Skip to content
20-F

Annual Report (Foreign)

Universe Pharmaceuticals INC UPC

0001213900-25-036798

← back to feed
Filed
Apr 29, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Sep 30, 2024 23.65M sh
Short Term Debt FY 2024 · Sep 30, 2023 $5.48M
Current Liabilities restated FY 2024 · Sep 30, 2023 $13.75M
Total Liabilities FY 2024 · Sep 30, 2023 $13.75M
Current Assets restated FY 2024 · Sep 30, 2023 $25.27M
Total Assets restated FY 2024 · Sep 30, 2023 $41.72M
Shares Diluted restated FY 2024 · Sep 30, 2022 6.04K sh
Capex FY 2024 · Sep 30, 2022 $93.7K
Operating Cash Flow restated FY 2024 · Sep 30, 2022 −$1.3M
Eps Diluted restated FY 2024 · Sep 30, 2022 −$1,309.11
Eps Basic restated FY 2024 · Sep 30, 2022 −$1,309.11
Sga Expense restated FY 2024 · Sep 30, 2022 $2.18M
Rd Expense FY 2024 · Sep 30, 2022 $7.64M
Net Income restated FY 2024 · Sep 30, 2022 −$7.91M
Operating Income restated FY 2024 · Sep 30, 2022 −$7.02M
Gross Profit FY 2024 · Sep 30, 2022 $21.89M
Cost Of Revenue FY 2024 · Sep 30, 2022 $18.25M
Revenue FY 2024 · Sep 30, 2022 $40.14M
Stockholders Equity restated FY 2024 · Sep 30, 2021 $46.99M